Suzhou News | The Light of Science and Technology Guides Precise Surgeries, Illuminating Tumors and Benefiting Thousands of Patients.

The first near-infrared tumor-targeted fluorescent contrast agent product to receive clinical approval in China.

Tumor-targeted fluorescent contrast agent.

Tumor-targeted fluorescent contrast agent is a new type of molecular imaging contrast agent, which can be specifically combined with tumors and accurately illuminate invisible residual malignant lesions intraoperatively via near-infrared imaging system.

                                                               

Real-time localization of tumor tissues.
Specific binding with tumors to "light up" tumor tissues.

Precise determination of positive resection margins.
Clear distinction between tumor and non-tumor areas.

Detection of hidden and tiny lesions.
Identification of tumor tissues that are indistinguishable to the naked eye.

Recognition of positive lymph nodes.

High recognition rate for metastatic lymph nodes.

Identification of important tissues and structures.
Recognition of important structural tissues and organs.

                                                                  

                                                                                     Innovation Promotes Development

The power of innovative science and technology has played an important role in the current path of the country's high-quality development. In the fields of tumor treatment and intraoperative tumor localization, a number of "special forces" have emerged. Taking high and new technologies as their "sharp weapons", they use new types of agents to safeguard the lives and health of patients, improve the survival rate of patients, fight against diseases, and have made great contributions to patients' health. As a vanguard in this regard, SIGNDO has won high recognition both inside and outside the industry with its independently developed tumor-targeted fluorescent contrast agents. It was also reported in a large section on the "Suzhou News Network" program broadcast on the Suzhou News Integrated Channel this week.

                                                                

                                                                  Innovation promotes development. Hand in hand, we make progress together.

                                                               

SIGNDO was founded in February 2021 and is an innovative biotechnology company focusing on the research and development and industrialization of tumor-targeted fluorescent contrast agents and related field products. Since its establishment, the company has been committed to providing doctors with the tools necessary for tumor visualization. With the goal of "lighting up tumors and enabling precise surgeries", it helps surgeons achieve more complete surgical resections and helps cancer patients improve their quality of life. SIGNDO has a globally leading RTTFC® technology platform. It uses small molecule fluorescence coupling technology to build a multi-cancer product portfolio for intraoperative visualization of real-time tumors. It is dedicated to becoming a leader in domestic targeted fluorescent contrast agents.